论文部分内容阅读
目的 探讨非小细胞肺癌 (NSCLC)患者血清中IL 1 0的水平在肿瘤发生、发展、转移和预后中的作用及其临床意义。方法 选择TNM分期为Ⅲ～Ⅳ期的NSCLC患者 44例 ,其中 30例接受以铂类药为主的化疗 ;另选 30例健康成人作为对照组。在治疗前及治疗后 1个月应用ELISA测定血清IL 1 0水平。结果 所有患者血清中的IL 1 0水平 (ng/L)均高于健康对照组 (1 92 37± 1 3 46vs 84 2 0± 2 1 7,P<0 0 1 ) ;Ⅳ期的NSCLC患者血清IL 1 0水平 (ng/L)高于Ⅲ期NSCLC患者 (2 68 2 7± 2 5 0 3vs 1 51 1 6± 1 0 2 0 ,P <0 0 1 )。 1个疗程后 1个月有 1 8例病情稳定或肿瘤部分缩小 ,1 2例治疗无效。治疗有效者的血清IL 1 0水平 (ng/L)降低 (2 0 8 1 8± 2 0 0 5vs 1 2 9 96± 1 4 2 2 ,P <0 0 5) ;治疗无效者的血清IL 1 0水平 (ng/L)略低于治疗前 (1 75 54± 1 3 60vs 1 62 1 3± 1 1 69,P >0 0 5)。结论 血清IL 1 0水平与NSCLC的发生及其转移相关 ,提示IL 1 0在NSCLC的发生和发展中起着某种重要的作用 ,测定血清IL 1 0水平具有一定的临床意义
Objective To investigate the role and clinical significance of IL 10 in serum of patients with non-small cell lung cancer (NSCLC) in tumorigenesis, progression, metastasis and prognosis. Methods Forty-four NSCLC patients with stage III to IV TNM staging were selected, 30 of whom received platinum-based chemotherapy; 30 healthy adults were selected as the control group. Serum IL 10 levels were measured by ELISA before treatment and one month after treatment. Results The serum levels of IL 10 in all patients (ng/L) were higher than those in the healthy control group (1 92 37±13 46 vs 84 2 0±2 17 P<0 01); patients with stage IV NSCLC sera IL 1 0 levels (ng/L) were higher in patients with stage III NSCLC (2 68 2 7 ± 2 5 0 vs 1 51 16 ± 1 0 2 0, P <0 01). After 1 course of 1 course, there were 18 cases with stable disease or a partial shrinkage of the tumor, and 12 cases were ineffective. Serum levels of IL 1 0 (ng/L) decreased in the responders (28 08 ± 2 0 0 5 vs 1 2 9 96 ± 1 4 2 2 , P <0 05); serum IL 1 in patients who did not respond to treatment The level of 0 (ng/L) was slightly lower than before treatment (1 75 54 ± 1 3 60 vs 1 62 1 3 ± 1 1 69, P > 0 05). Conclusion Serum IL 10 levels are related to the occurrence and metastasis of NSCLC, suggesting that IL 10 plays an important role in the occurrence and development of NSCLC. Measuring serum IL 10 levels has certain clinical significance.